Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
Acumen Pharmaceuticals' Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer's disease missed its primary endpoint (iADRS at 18 months) at both the 35 mg/kg and 50 mg/kg doses, and key secondary endpoints including CDR-SB also failed to reach statistical significance. The company will cease clinical development of sabirnetug, including the open-label extension, implement cash conservation measures, and explore strategic options including its Enhanced Brain Delivery program.
Key figures
- Drug Name
- sabirnetug (ACU193)
- Phase Of Trial
- Phase 2
- Trial name
- ALTITUDE-AD
- Doses tested
- ["35 mg/kg","50 mg/kg"]
- Aria e incidence
- ~10%
- Primary endpoint
- iADRS change from baseline at 18 months
- Enrolled participants
- 542
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.